**American Association of Clinical Endocrinologists**
**Texas Chapter of AACE Annual Meeting**
and
**The Texas Endocrine Surgical Symposium**

August 4-5, 2017
Grand Hyatt San Antonio
600 E Market St
San Antonio, TX 78205

**PROGRAM COMMITTEE**
Robert Hood, MD, FRCP, FACE; Co-Chair
Terry Lairmore, MD, FACS; Co-Chair
Tom Blevins, MD, FACE, ECNU
Alan Dackiw, MD, PhD, MBA, FACS
Kathleen Hands, MD, FACE, ECNU
Lindsey Harrison, MD, ECNU
Kathy LaCivita, MD, FACP, FACE
Kerem Ozer, MD, ECNU
Sue Samson, MD, PhD, FRCPC, FACE
Heidi Shea, MD, FACE

**Friday, August 4, 2017**

7:00 – 8:00 a.m.  Continental Breakfast

8:00 – 8:30 a.m.  Welcoming Remarks & Pre Meeting Assessment
Objectives:
1. After participating in a pre-meeting assessment tool, attendees will be able to recognize areas of potential shortcoming and strive to improve knowledge and consequential healthcare practices

**Session 1 – Diabetes / Metabolic**

8:30 – 9:05 a.m.  A Cardiovascular Diagnosis & GLP1/SGLT2
Robert Chilton, DO, FACC
Objectives:
1. Understand the cardiovascular effects from GLP1 & SGLT2 trials
2. Risk and benefits of these new cardiovascular agents in diabetes
3. Understand yearly event rate in diabetes of new trials

9:05 – 9:40 a.m.  Systematically Assessing the Promise of Diabetes Remission
Hertzel C. Gerstein, MD, MSc, FRCPC
Objectives:
1. Define type 2 diabetes remission
2. Analyze the evidence base in support of remission of type 2 diabetes and understand a systematic approach to studying it
3. Differentiate diabetes remission and prevention

9:40 – 10:15 a.m.  Metabolic Insights into Non-Alcoholic Fatty Liver Disease: The overlooked complication of type 2 diabetes
Kenneth Cusi, MD, FACP, FACE
Objectives:
1. Increase awareness on the role of insulin resistance, diabetes and ethnicity to the development of non-alcoholic fatty liver disease
2. Understand dilemmas that the endocrinologist faces in the diagnosis and management of such patients
3. Review the choices and expected benefits of current treatments for non-alcoholic fatty liver disease
10:15 – 10:45 a.m. **Break**

10:45 – 11:20 a.m. **Interesting Cases**

**Fasting Hypoglycemia in a Previously Healthy Nurse**

Henry Reinhart, MD

Objectives:
1. Define the orderly workup and differential diagnosis for fasting hypoglycemia
2. Identify the clinical and pathologic features of adult nesidioblastosis

**An Unusual Cause of Hypoglycemia**

Stacey Milan, MD, FACS

Objectives:
1. Identify indications for work up of hypoglycemia
2. Recognize obscure causes of hypoglycemia in a diabetic patient

11:20 – 11:55 a.m. **Surgical Management of Endogenous Hyperinsulinism**

Terry C. Lairmore, MD, FACS

Objectives:
1. Recognize the essential elements of the diagnostic workup to establish the presence of surgically correctable (endogenous) hyperinsulinism
2. Understand the current role of preoperative imaging tests for patients with insulinoma
3. Describe the current surgical approach and strategy for resection of solitary insulinoma, noninsulinoma pancreatogenous hypoglycemia, and adult nesidioblastosis

11:55 – 12:15 p.m. **Diabetes / Metabolic Panel Discussion**

Robert Chilton, DO, FACC; Hertzel C. Gerstein, MD, MSc, FRCPC; Kenneth Cusi, MD, FACP, FACE; Terry C. Lairmore, MD, FACS

Objectives:
1. Allow the audience to further explore and clarify issues related to the morning's presentations with the faculty

12:30 – 2:00 p.m. **Lunch**

**Session 2 – Adrenal / Pituitary / Neuroendocrine Section**

2:00 – 2:35 p.m. **Controversies in the Management of Primary Hyperaldosteronism**

Alan Dackiw, MD, PhD, MBA, FACS

Objectives:
1. Describe the investigations and differential diagnosis of hyperaldosteronism
2. Interpret the results of adrenal vein sampling in patients with hyperaldosteronism
3. Describe the medical and surgical management of hyperaldosteronism

2:35 – 3:05 p.m. **Current Management of Adrenal Cortical Carcinoma**

Jeffrey E. Lee, MD

Objectives:
1. Discuss the optimal surgical approaches for management of patients with adrenal cortical carcinoma
2. Summarize the potential indications for adjuvant and neoadjuvant systemic treatment of adrenal cortical carcinoma
3. Describe current and potential future systemic treatment options for patients with advanced adrenal cortical carcinoma

3:05 – 3:40 p.m. **Break**
3:40 – 4:15 p.m. **Challenging Pituitary Cases**
Thomas Blevins, MD, FNLA, FACE, ECNU; Sue Samson, MD, PhD, FRCPC, FACE
Objectives:
1. Recognize the prevalence of persistent and recurrent disease following surgical remission of Cushing’s disease and acromegaly
2. Debate the patient specific characteristics which could be appropriate for treatment with mifepristone or pasireotide
3. Discuss indications for mifepristone, pasireotide, in the treatment of Cushing’s syndrome and acromegaly

4:15 – 4:45 p.m. **Post Meeting Assessment**
Objectives:
1. At the conclusion of the meeting, attendees will be able to measure learning that occurred that will enable the use of new healthcare techniques and practices and to review or confirm existing care modalities.

4:45 – 5:30 p.m. **TX-AACE Chapter Business Meeting / Reception**
Saturday, August 5, 2017
6:45 – 7:40 a.m.  Continental Breakfast

7:40 – 8:05 a.m.  Welcome / Pre Meeting Assessment
Objectives:
1. After participating in a pre-meeting assessment tool, attendees will be able to recognize areas of potential shortcoming and strive to improve knowledge and consequential healthcare practices.

Session 3 – Thyroid Section

8:05 – 9:05 a.m.  Pros / Cons Central Lymph Node Dissection
There is no role for Prophylactic Central Compartment Neck Dissection
Christopher McHenry, MD
Routine Central Lymph Node Dissection Should be Performed in Patients with Papillary Thyroid Cancer
Samuel Snyder, MD, FACS
Objectives:
1. Describe a central node dissection and differentiate a therapeutic and prophylactic central neck dissection
2. Define the role of central node dissection in the management of papillary thyroid cancer
3. Review the controversy surrounding prophylactic central node dissection in patients with clinically node negative disease

Approved for ECNU recertification CME credit

9:05 – 9:40 a.m.  Timing of Early Preventative Thyroidectomy in Children with MEN 2
Terry C. Lairmore, MD, FACS
Objectives:
1. Describe the genotype-phenotype relationships of various RET protooncogene mutations in children with MEN2
2. Understand the basis for current recommendations of timing of early thyroidectomy based on mutation risk stratification
3. Understand the current controversies regarding extent of cervical lymphadenectomy and management of the parathyroid glands in children undergoing early thyroidectomy for MEN2

9:40 – 10:10 a.m.  Break

10:10 – 10:45 a.m.  Graves Ophthalmopathy: Advances in diagnosis and treatment
Constance Fry, MD
Objectives:
1. Identify causes of enlarged extraocular muscles that can mimic Graves ophthalmopathy
2. Explain the role of corticosteroids in the treatment of Graves ophthalmopathy
3. Summarize the individualized approach to medical and surgical treatment of Graves ophthalmopathy to optimize results

10:45 – 11:20 p.m.  Management of the Recurrent Laryngeal Nerve at the Ligament of Berry:
Implications for the endocrinologist and surgeon
Nathan Hales, MD, FACS
Objectives:
1. Review the anatomy of the recurrent laryngeal nerve and its association with the ligament of berry and tubercle of zuckerkandl, injury rates and implications
2. Discuss management of the tubercle of zuckerkandl during thyroid surgery
3. Implications of inadequate management of the tubercle of zuckerkandl/ligament of berry for the endocrinologist
11:20 – 11:55 p.m. **Thyroid Panel Discussion**
Christopher McHenry, MD; Samuel Snyder, MD, FACS; Terry C. Lairmore, MD, FACS; Constance Fry, MD; Nathan Hales, MD, FACS
Objectives:
1. Allow the audience to further explore and clarify issues related to the morning's presentations with the faculty

11:55 – 1:30 p.m. **Lunch**

**Session 4 – Bone Section**

1:30 – 2:15 p.m. **Osteoporosis & Drug Classes – A Case-based Discussion**
Laila Tabatabai, MD
Objectives:
1. Determine which patients with low bone density require treatment, along with optimal duration of treatment
2. Select antiresorptive agents based on the patient's individual characteristics and preferences
3. Recognize the benefits of anabolic agents in specific subpopulations of osteoporosis patients

2:15 – 2:45 p.m. **Parathyroid Imaging: Current Concepts**
Maria Gules-Monroe, MD
Objectives:
1. 4D-CT evaluation of hyperparathyroidism
2. Ultrasound characteristics of parathyroid adenomas vs. lymph nodes
3. Intraoperative support for minimally invasive parathyroidectomy and localization of transplanted parathyroid tissue

2:45 – 3:20 p.m. **Hypoparathyroidism - A Case-based Discussion**
Mimi Hu, MD
Objectives:
1. Understand the etiologies of hypoparathyroidism
2. Discuss the medical treatment of hypoparathyroidism
3. Understand the use of parathyroid hormone in hypoparathyroidism

3:20 – 3:55 p.m. **Interesting Cases**
3:20 – 3:35 *Real pregnancy or uncontrolled hypothyroidism?*
Christie G. Turin, MD

3:35 – 3:50 *An Adult with a very low alkaline phosphatase*
Thomas Blevins, MD, FNLA, FACE, ECNU

3:50 – 3:55 Q&A
Objectives:
1. Through fellow presentations, allow the audience to learn and participate in the evaluation of usual medical cases.

3:55 – 4:30 p.m. **Post Meeting Assessment / Adjourn**
Objectives:
1. At the conclusion of the meeting, attendees will be able to measure learning that occurred that will enable the use of new healthcare techniques and practices and to review or confirm existing care modalities.